Bluegrass Pharmaceuticals
Research increasingly demonstrates that an over-active immune system and the resulting spikes in inflammation, are actually worse for healing. When injury first occurs, tissue specific macrophages initiate the inflammatory cascade by releasing cytokines into the blood stream. These inflammatory markers recruit additional macrophages to the site of injury. In chronic or deleterious forms of inflammation, these recruited macrophages arrive at the scene in M1 or “destructive” phenotype, long after necrotic tissue or pathogens are removed; causing unnecessary damage and perpetuating the cycle of inflammation. Our NF-kB blocker leverages a nano-particle delivery system to target and re-polarize recruited macrophages to the M2 or “restorative” phenotype, moderating inflammation and improving remodeling.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
2
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Bluegrass Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Bluegrass Pharmaceuticals
2 distinct titles indexed · top 2 shown.
- 1co-founder
- 1founder
Sign up to unlock all 2 contacts at Bluegrass Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Bluegrass Pharmaceuticals
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.